Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Dec:21:23259582221109613.
doi: 10.1177/23259582221109613.

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania

Ritah F Mutagonda  1 , Hamu J Mlyuka  1 , Betty A Maganda  2 , Appolinary A R Kamuhabwa  1
Affiliations

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania

Ritah F Mutagonda et al. J Int Assoc Provid AIDS Care. 2022 Jan-Dec.

Abstract

Objectives:This study aimed at assessing adherence, effectiveness, and safety of DTG-based HAART regimens among HIV-infected children and adolescents in Tanzania. Methods: This was a single-center prospective cohort study, conducted at the pediatric HIV Clinic in Mbeya, Tanzania. A binary logistic regression model was used to determine predictors of undetectable viral load at week 24. The results were significant when P-value was <0.05. Results: A total of 200 patients were enrolled with the majority (85.5%) being treatment experienced. High adherence levels (71%) were observed using the pharmacy refill method. At week 24, the overall proportion of patients with undetectable viral load was 70.2%. The predictors of undetectable viral load were age, World Health Organization (WHO) clinical stage, baseline VL and adherence to pharmacy refill. Conclusion: The majority of patients attained undetectable viral load 6 months after using DTG based regimen. DTG-based regimens were generally safe with few ADEs reported.

Keywords: Adherence; Adolescents; Children; Dolutegravir; Effectiveness; HIV/AIDs; Safety.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Estimation of adherence levels by self-reporting and pharmacy refill methods.
Figure 2.
Figure 2.
Immunological outcomes at baseline and 6-months after using DTG-based regimen.
Figure 3
Figure 3
(A) Virological outcomes at baseline, 6-months and 1-year after using DTG based regimen. (B) Virological outcomes among treatment naïve and experienced patients 6-months after using DTG-based regimen.
Figure 4.
Figure 4.
Adverse drug events reported among patients on DTG regimen (n = 33).
See this image and copyright information in PMC

References

    1. UNICEF. Global and Regional trends 2019; https://data.unicef.org/topic/hivaids/globalregional-trends/. Accessed on 17th December 2021.
    1. United Republic of Tanzania. Country Profile. UNAIDS Data. Joint United Nations Programme on HIV/AIDS 2018. http://www.unaids.org/en/resources/documents/2018/unaids-data-2018. Accessed on 17th December 2021.
    1. Tanzania HIV Impact Survey (THIS). A population-based HIV impact assessment 2016-2017. January 2018. https://www.nbs.go.tz/nbs/takwimu/this2016-17/Tanzania_SummarySheet_Engl.... Accessed on 17th December 2021.
    1. World Health Organization. Global Health Observatory (GHO) data. HIV/ AIDS 2018; https://www.who.int/gho/hiv/en/. Accessed on 17th December 2021.
    1. Dorward J, Lessells R, Drain PK, et al. Dolutegravir for first-line antiretroviral therapy in low- and middle-income countries: uncertainties and opportunities for implementation and research. 10.1016/S2352-3018(18)30093-6. Accessed on 17th December 2021. - DOI - PMC - PubMed

Publication types